Literature DB >> 28597597

Sinus hypoplasia in the cystic fibrosis rat resolves in the absence of chronic infection.

Jessica Grayson1, Kiranya E Tipirneni2, Daniel F Skinner1,3, Matthew Fort1, Do-Yeon Cho1,3, Shaoyan Zhang1,3, Andrew C Prince4, Dong-Jin Lim1,3, Calvin Mackey1,3, Bradford A Woodworth1,3.   

Abstract

BACKGROUND: Sinus hypoplasia is a hallmark characteristic in cystic fibrosis (CF). Chronic rhinosinusitis (CRS) is nearly universal from a young age, impaired sinus development could be secondary to loss of the cystic fibrosis transmembrane conductance regulator (CFTR) or consequences of chronic infection during maturation. The objective of this study was to assess sinus development relative to overall growth in a novel CF animal model.
METHODS: Sinus development was evaluated in CFTR-/- and CFTR+/+ rats at 3 stages of development: newborn; 3 weeks; and 16 weeks. Microcomputed tomography (microCT) scanning, cultures, and histology were performed. Three-dimensional sinus and skull volumes were quantified.
RESULTS: At birth, sinus volumes were decreased in CFTR-/- rats compared with wild-type rats (mean ± SEM: 11.3 ± 0.85 mm3 vs 14.5 ± 0.73 mm3 ; p < 0.05), despite similar weights (8.4 ± 0.46 gm vs 8.3 ± 0.51 gm; p = 0.86). CF rat weights declined by 16 weeks (378.4 ± 10.6 gm vs 447.4 ± 15.9 gm; p < 0.05), sinus volume increased similar to wild-type rats (201.1 ± 3.77 gm vs 203.4 ± 7.13 gm; p = 0.8). The ratio of sinus volume to body weight indicates hypoplasia present at birth (1.37 ± 0.12 vs 1.78 ± 0.11; p < 0.05) and showed an increase compared with CFTR+/+ animals by 16 weeks (0.53 ± 0.02 vs 0.46 ± 0.02; p < 0.05). Rats did not develop histologic evidence of chronic infection.
CONCLUSION: CF rat sinuses are smaller at birth, but develop volumes similar to wild-type rats with maturation. This suggests that loss of CFTR may confer sinus hypoplasia at birth, but normal development ensues without chronic sinus infection.
© 2017 ARS-AAOA, LLC.

Entities:  

Keywords:  CF rat; CFTR; animal models; chronic rhinosinusitis; chronic sinusitis; cystic fibrosis; sinus development; sinus hypoplasia; sinusitis

Mesh:

Substances:

Year:  2017        PMID: 28597597      PMCID: PMC5587374          DOI: 10.1002/alr.21973

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  20 in total

1.  Characterization of primary rat nasal epithelial cultures in CFTR knockout rats as a model for CF sinus disease.

Authors:  Kiranya E Tipirneni; Do-Yeon Cho; Daniel F Skinner; Shaoyan Zhang; Calvin Mackey; Dong-Jin Lim; Bradford A Woodworth
Journal:  Laryngoscope       Date:  2017-08-03       Impact factor: 3.325

2.  Paranasal sinus development in chronic sinusitis, cystic fibrosis, and normal comparison population: a computerized tomography correlation study.

Authors:  H J Kim; E M Friedman; M Sulek; N O Duncan; C McCluggage
Journal:  Am J Rhinol       Date:  1997 Jul-Aug

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition.

Authors:  H C Lai; M R Kosorok; S A Sondel; S T Chen; S C FitzSimmons; C G Green; G Shen; S Walker; P M Farrell
Journal:  J Pediatr       Date:  1998-03       Impact factor: 4.406

Review 5.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.

Authors:  Scott D Grosse; Coleen A Boyle; Jeffrey R Botkin; Anne Marie Comeau; Martin Kharrazi; Margaret Rosenfeld; Benjamin S Wilfond
Journal:  MMWR Recomm Rep       Date:  2004-10-15

6.  The delta F508 mutation in cystic fibrosis and impact on sinus development.

Authors:  Bradford A Woodworth; Chadwick Ahn; Patrick A Flume; Rodney J Schlosser
Journal:  Am J Rhinol       Date:  2007 Jan-Feb

Review 7.  What have we learned from mouse models for cystic fibrosis?

Authors:  Isabel Carvalho-Oliveira; Bob J Scholte; Deborah Penque
Journal:  Expert Rev Mol Diagn       Date:  2007-07       Impact factor: 5.225

8.  Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer.

Authors:  Christopher S Rogers; Yanhong Hao; Tatiana Rokhlina; Melissa Samuel; David A Stoltz; Yuhong Li; Elena Petroff; Daniel W Vermeer; Amanda C Kabel; Ziying Yan; Lee Spate; David Wax; Clifton N Murphy; August Rieke; Kristin Whitworth; Michael L Linville; Scott W Korte; John F Engelhardt; Michael J Welsh; Randall S Prather
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis.

Authors:  H B Eggesbø; S Søvik; S Dølvik; K Eiklid; F Kolmannskog
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

10.  Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.

Authors:  Katherine L Tuggle; Susan E Birket; Xiaoxia Cui; Jeong Hong; Joe Warren; Lara Reid; Andre Chambers; Diana Ji; Kevin Gamber; Kengyeh K Chu; Guillermo Tearney; Li Ping Tang; James A Fortenberry; Ming Du; Joan M Cadillac; David M Bedwell; Steven M Rowe; Eric J Sorscher; Michelle V Fanucchi
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

View more
  1 in total

1.  Korean Red Ginseng aqueous extract improves markers of mucociliary clearance by stimulating chloride secretion.

Authors:  Do-Yeon Cho; Daniel Skinner; Shaoyan Zhang; Ahmed Lazrak; Dong Jin Lim; Christopher G Weeks; Catherine G Banks; Chang Kyun Han; Si-Kwan Kim; Guillermo J Tearney; Sadis Matalon; Steven M Rowe; Bradford A Woodworth
Journal:  J Ginseng Res       Date:  2019-09-13       Impact factor: 6.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.